Management, survival, and costs of pancreatic cancer: Popupation-Based observational study in Catalonia

Abstract: Aim: Few published studies comprehensively describe the characteristics of patients with pancreatic cancer and their treatment in clinical practice. This study aimed to describe the current clinical practice for treating pancreatic cancer in Catalonia, along with the associated survival an...

Descripción completa

Detalles Bibliográficos
Autores: Guarga, Laura, Paco, Noelia, Manchon Walsh, Paula, Vela, Emili, Delgadillo, Joaquim, Pontes, Caridad, Borràs Andrés, Josep Maria
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/226961
Acceso en línea:https://hdl.handle.net/2445/226961
Access Level:acceso abierto
Palabra clave:Càncer de pàncrees
Pancreatitis
Pancreatografia
Pancreas cancer
Pancreatography
id ES_226555ebf5efb967cd6503f6ea8d83aa
oai_identifier_str oai:diposit.ub.edu:2445/226961
network_acronym_str ES
network_name_str España
repository_id_str
spelling Management, survival, and costs of pancreatic cancer: Popupation-Based observational study in CataloniaGuarga, LauraPaco, NoeliaManchon Walsh, PaulaVela, EmiliDelgadillo, JoaquimPontes, CaridadBorràs Andrés, Josep MariaCàncer de pàncreesPancreatitisPancreatografiaPancreas cancerPancreatitisPancreatographyAbstract: Aim: Few published studies comprehensively describe the characteristics of patients with pancreatic cancer and their treatment in clinical practice. This study aimed to describe the current clinical practice for treating pancreatic cancer in Catalonia, along with the associated survival and treatment costs. Methods: A retrospective observational cohort study in patients diagnosed with pancreatic cancer from 2014 to 2018, using data from the healthcare records of the Public Health System of Catalonia, was conducted. Treatment patterns and costs were described by age groups</p><p>from 2014 to 2018, with survival reported until December 2021. Results: The proportion of patients receiving surgery with curative intent was low, especially in older patients (23% of patients <60 years and 9% of patients 80 years). The percentage of patients treated with drugs for unresectable disease also decreased with age (45% of patients <60 years and 8% of patients 80 years). Although age was associated with significant differences in survival after curative surgery, no differences attributable to age were observed in patients who received pharmacological treatment for unresectable disease. In patients under 60 years of age, the mean cost of the first year of treatment was EUR 17,730 (standard</p><p>deviation [SD] 5754) in those receiving surgery and EUR 5398 (SD 9581) in those on pharmacological treatment for unresectable disease. In patients over 80, the mean costs were EUR 15,339 (SD 2634) and EUR 1845 (SD 3413), respectively. Conclusions: Half of the patients diagnosed with pancreatic cancer did not receive specific treatment. Surgery with curative intent was associated with longer survival, but only 18% of (mostly younger) patients received this treatment. Chemotherapy was also used less frequently in patients of advanced age, though survival in treated patients was comparable across all age groups, so careful oncogeriatric assessment is advisable to ensure the most appropriate indication for eligibility in older patients. In general, earlier diagnosis and more effective pharmacological treatments are necessary to treat frail patients with high comorbidity, a common profile in older patients.MDPI2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/226961Articles publicats en revistes (Ciències Clíniques)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/ijerph20095673International Journal of Environmental Research and Public Health, 2023, vol. 20, num.9, p. 5673https://doi.org/10.3390/ijerph20095673cc-by (c) Guarga, L. et al., 2023http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2269612026-05-27T06:46:51Z
dc.title.none.fl_str_mv Management, survival, and costs of pancreatic cancer: Popupation-Based observational study in Catalonia
title Management, survival, and costs of pancreatic cancer: Popupation-Based observational study in Catalonia
spellingShingle Management, survival, and costs of pancreatic cancer: Popupation-Based observational study in Catalonia
Guarga, Laura
Càncer de pàncrees
Pancreatitis
Pancreatografia
Pancreas cancer
Pancreatitis
Pancreatography
title_short Management, survival, and costs of pancreatic cancer: Popupation-Based observational study in Catalonia
title_full Management, survival, and costs of pancreatic cancer: Popupation-Based observational study in Catalonia
title_fullStr Management, survival, and costs of pancreatic cancer: Popupation-Based observational study in Catalonia
title_full_unstemmed Management, survival, and costs of pancreatic cancer: Popupation-Based observational study in Catalonia
title_sort Management, survival, and costs of pancreatic cancer: Popupation-Based observational study in Catalonia
dc.creator.none.fl_str_mv Guarga, Laura
Paco, Noelia
Manchon Walsh, Paula
Vela, Emili
Delgadillo, Joaquim
Pontes, Caridad
Borràs Andrés, Josep Maria
author Guarga, Laura
author_facet Guarga, Laura
Paco, Noelia
Manchon Walsh, Paula
Vela, Emili
Delgadillo, Joaquim
Pontes, Caridad
Borràs Andrés, Josep Maria
author_role author
author2 Paco, Noelia
Manchon Walsh, Paula
Vela, Emili
Delgadillo, Joaquim
Pontes, Caridad
Borràs Andrés, Josep Maria
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Càncer de pàncrees
Pancreatitis
Pancreatografia
Pancreas cancer
Pancreatitis
Pancreatography
topic Càncer de pàncrees
Pancreatitis
Pancreatografia
Pancreas cancer
Pancreatitis
Pancreatography
description Abstract: Aim: Few published studies comprehensively describe the characteristics of patients with pancreatic cancer and their treatment in clinical practice. This study aimed to describe the current clinical practice for treating pancreatic cancer in Catalonia, along with the associated survival and treatment costs. Methods: A retrospective observational cohort study in patients diagnosed with pancreatic cancer from 2014 to 2018, using data from the healthcare records of the Public Health System of Catalonia, was conducted. Treatment patterns and costs were described by age groups</p><p>from 2014 to 2018, with survival reported until December 2021. Results: The proportion of patients receiving surgery with curative intent was low, especially in older patients (23% of patients <60 years and 9% of patients 80 years). The percentage of patients treated with drugs for unresectable disease also decreased with age (45% of patients <60 years and 8% of patients 80 years). Although age was associated with significant differences in survival after curative surgery, no differences attributable to age were observed in patients who received pharmacological treatment for unresectable disease. In patients under 60 years of age, the mean cost of the first year of treatment was EUR 17,730 (standard</p><p>deviation [SD] 5754) in those receiving surgery and EUR 5398 (SD 9581) in those on pharmacological treatment for unresectable disease. In patients over 80, the mean costs were EUR 15,339 (SD 2634) and EUR 1845 (SD 3413), respectively. Conclusions: Half of the patients diagnosed with pancreatic cancer did not receive specific treatment. Surgery with curative intent was associated with longer survival, but only 18% of (mostly younger) patients received this treatment. Chemotherapy was also used less frequently in patients of advanced age, though survival in treated patients was comparable across all age groups, so careful oncogeriatric assessment is advisable to ensure the most appropriate indication for eligibility in older patients. In general, earlier diagnosis and more effective pharmacological treatments are necessary to treat frail patients with high comorbidity, a common profile in older patients.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/226961
url https://hdl.handle.net/2445/226961
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/ijerph20095673
International Journal of Environmental Research and Public Health, 2023, vol. 20, num.9, p. 5673
https://doi.org/10.3390/ijerph20095673
dc.rights.none.fl_str_mv cc-by (c) Guarga, L. et al., 2023
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Guarga, L. et al., 2023
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404579118972928
score 15,812429

Similares en LA Referencia